These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23702275)

  • 1. Rational design of lyophilized high concentration protein formulations-mitigating the challenge of slow reconstitution with multidisciplinary strategies.
    Cao W; Krishnan S; Ricci MS; Shih LY; Liu D; Gu JH; Jameel F
    Eur J Pharm Biopharm; 2013 Oct; 85(2):287-93. PubMed ID: 23702275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.
    Telikepalli S; Kumru OS; Kim JH; Joshi SB; O'Berry KB; Blake-Haskins AW; Perkins MD; Middaugh CR; Volkin DB
    J Pharm Sci; 2015 Feb; 104(2):495-507. PubMed ID: 25522000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability characterization and appearance of particulates in a lyophilized formulation of a model peptide hormone-human secretin.
    Srinivasan C; Siddiqui A; Korang-Yeboah M; Khan MA
    Int J Pharm; 2015 Mar; 481(1-2):104-13. PubMed ID: 25636302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11).
    Hirakura Y; Kojima S; Okada A; Yokohama S; Yokota S
    Int J Pharm; 2004 Nov; 286(1-2):53-67. PubMed ID: 15501002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation development of lyophilized, long-term stable siRNA/oligoaminoamide polyplexes.
    Kasper JC; Troiber C; Küchler S; Wagner E; Friess W
    Eur J Pharm Biopharm; 2013 Oct; 85(2):294-305. PubMed ID: 23747745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the influence of the cooling profile on the reconstitution times of amorphous lyophilized protein formulations.
    Beech KE; Biddlecombe JG; van der Walle CF; Stevens LA; Rigby SP; Burley JC; Allen S
    Eur J Pharm Biopharm; 2015 Oct; 96():247-54. PubMed ID: 26253503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation approach for the development of a stable, lyophilized formaldehyde-containing vaccine.
    Clausi A; Chouvenc P
    Eur J Pharm Biopharm; 2013 Oct; 85(2):272-8. PubMed ID: 23673385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.
    Awotwe-Otoo D; Agarabi C; Wu GK; Casey E; Read E; Lute S; Brorson KA; Khan MA; Shah RB
    Int J Pharm; 2012 Nov; 438(1-2):167-75. PubMed ID: 22944306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulating monoclonal antibodies as powders for reconstitution at high concentration using spray drying: Models and pitfalls.
    Batens M; Massant J; Teodorescu B; Van den Mooter G
    Eur J Pharm Biopharm; 2018 Jun; 127():407-422. PubMed ID: 29499299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reconstitution of Highly Concentrated Lyophilized Proteins: Part 1 Amorphous Formulations.
    Sane P; Bogner RH; Bhatnagar B; Tchessalov S
    J Pharm Sci; 2020 May; 109(5):1681-1691. PubMed ID: 32070705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations.
    Roy S; Jung R; Kerwin BA; Randolph TW; Carpenter JF
    J Pharm Sci; 2005 Feb; 94(2):382-96. PubMed ID: 15614819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of annealing lyophilized and spray-lyophilized formulations of recombinant human interferon-gamma.
    Webb SD; Cleland JL; Carpenter JF; Randolph TW
    J Pharm Sci; 2003 Apr; 92(4):715-29. PubMed ID: 12661058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standardization of the Reconstitution Procedure of Protein Lyophilizates as a Key Parameter to Control Product Stability.
    Traub-Hoffmann K; Furtmann B; Laber L; Helm S; Geiger C; Bussemer T
    J Pharm Sci; 2020 Jan; 109(1):211-215. PubMed ID: 31655034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20.
    Webb SD; Cleland JL; Carpenter JF; Randolph TW
    J Pharm Sci; 2002 Feb; 91(2):543-58. PubMed ID: 11835212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to Reduce Reconstitution Time of Lyophilized Biotherapeutics.
    Luoma J; Lim FJ
    J Pharm Sci; 2020 Jun; 109(6):1905-1911. PubMed ID: 32135168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of stable lyophilized protein drug products.
    Remmele RL; Krishnan S; Callahan WJ
    Curr Pharm Biotechnol; 2012 Mar; 13(3):471-96. PubMed ID: 22283723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can controlled ice nucleation improve freeze-drying of highly-concentrated protein formulations?
    Geidobler R; Konrad I; Winter G
    J Pharm Sci; 2013 Nov; 102(11):3915-9. PubMed ID: 23963664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solid-State Hydrogen-Deuterium Exchange Mass Spectrometry: Correlation of Deuterium Uptake and Long-Term Stability of Lyophilized Monoclonal Antibody Formulations.
    Moorthy BS; Zarraga IE; Kumar L; Walters BT; Goldbach P; Topp EM; Allmendinger A
    Mol Pharm; 2018 Jan; 15(1):1-11. PubMed ID: 29182876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface adsorption of recombinant human interferon-gamma in lyophilized and spray-lyophilized formulations.
    Webb SD; Golledge SL; Cleland JL; Carpenter JF; Randolph TW
    J Pharm Sci; 2002 Jun; 91(6):1474-87. PubMed ID: 12115847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key factors governing the reconstitution time of high concentration lyophilized protein formulations.
    Kulkarni SS; Patel SM; Suryanarayanan R; Rinella JV; Bogner RH
    Eur J Pharm Biopharm; 2021 Aug; 165():361-373. PubMed ID: 33974974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.